DEF: Bolt Biotherapeutics Announces 2025 Annual Meeting of Stockholders, Proposes Reverse Stock Split

Bolt Biotherapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 27, 2025, to vote on director elections, auditor ratification, and a proposed reverse stock split.

Summary

• Bolt Biotherapeutics will hold its 2025 Annual Meeting of Stockholders on May 27, 2025, virtually.
• Stockholders will vote on the election of two Class I directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and a reverse stock split of common stock.
• The reverse stock split ratio will be between 1-for-10 and 1-for-25, determined at the Board's discretion.
• The record date for the meeting is April 15, 2025, with 38,339,697 shares of common stock outstanding and entitled to vote.
• The Board recommends voting FOR the election of directors, ratification of the accounting firm, and the reverse stock split.
• The company is seeking to regain compliance with the Nasdaq Minimum Bid Requirement, which it was notified of on July 2, 2024.
• On January 6, 2025, Nasdaq notified the company of its eligibility to receive an additional 180 calendar day period to regain compliance with the Nasdaq Minimum Bid Requirement based on written notice of our intention to cure this deficiency by effecting a reverse stock split prior to June 30, 2025.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying information about the upcoming shareholder meeting and proposals. The need for a reverse stock split indicates underlying financial challenges, but the company is taking steps to address them.

Positives

• The Board is taking proactive steps to address the Nasdaq Minimum Bid Requirement by proposing a reverse stock split.
• Maintaining a Nasdaq listing is expected to improve market access and liquidity for the company's stock.
• The company has engaged with stockholders to ensure their views are heard by the Board.

Negatives

• The company is not currently in compliance with the Nasdaq Minimum Bid Requirement.
• A reverse stock split could negatively impact the marketability of existing shares.
• There is no guarantee that a reverse stock split will increase the stock price or maintain Nasdaq listing compliance.

Risks

• The reverse stock split may not increase the stock price proportionally or result in a permanent increase.
• The company may not continue to meet Nasdaq's continued listing requirements even after a reverse stock split.
• A reverse stock split could result in some stockholders owning odd lots, which may be more difficult to sell.
• The decrease in the number of shares outstanding as a consequence of a Reverse Stock Split and the anticipated increase in the market price of common stock could encourage interest in the common stock and possibly promote greater liquidity for stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the Reverse Stock Split.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through a reverse stock split and continue operating on the Nasdaq Capital Market.

Management Comments

• Mr. O'Callaghan possesses significant knowledge and experience in our industry and a deep understanding of our strategic objectives, all of which will benefit the Company during the year ahead.
• We believe that the separation of the positions of the Chair and chief executive officer reinforces the independence of the Board in its oversight of our business and affairs.
• In addition, we believe that having an independent Chair creates an environment that is more conducive to the Boards objective evaluation and oversight of managements performance, increasing management accountability, and improving the ability of the Board to monitor whether managements actions are in the best interests of the Company and its stockholders, including with respect to evaluating whether steps management is taking to manage risks are appropriate for the Company.

Industry Context

Many biotech companies face challenges in maintaining stock prices above the Nasdaq minimum, making reverse stock splits a relatively common strategy in the industry.

Comparison to Industry Standards

• Reverse stock splits are a common tool for companies facing delisting from major exchanges, with companies like Ocugen Inc. and CytoDyn Inc. having recently undertaken similar actions.
• The proposed reverse stock split ratio of 1-for-10 to 1-for-25 is within the typical range seen in similar situations.
• The company's audit fees are comparable to other small-cap biotech companies, with PricewaterhouseCoopers LLP being a reputable auditing firm.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a license agreement with Stanford University, where former board member Dr. Engleman is a professor and co-inventor of some licensed patents.
• The company entered into consulting agreements with former executive officers Randall C. Schatzman, Ph.D. and Edith Perez, M.D.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own due to the reverse stock split.
• Employees may be affected by the company's restructuring plan.
• The company's ability to raise capital and fund research and development could be impacted by its Nasdaq listing status.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on May 27, 2025.
• The Board will determine the final reverse stock split ratio, if approved.
• The company will file a certificate of amendment to effect the reverse stock split, if approved.
• The company will continue to monitor its stock price and compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, annual meeting, proxy statement, Nasdaq, directors, PricewaterhouseCoopers, stockholders, compliance, voting, Bolt Biotherapeutics